Humanigen Inc (HGENQ)

[cowtown jay]

"We have executed a non-binding letter of intent and are engaged in exclusive negotiations relating to a proposed business combination with a privately held biopharmaceutical company (the "Partner Company"). The proposed terms for the business combination contemplate a tax-free stock-for-stock merger, as a result of which we would issue shares of our capital stock to stockholders of the Partner Company which are expected to represent roughly two times the number of our currently outstanding shares of common stock."

https://www.marketscreener.com/quote/stock/HUMANIGEN-INC-25805137/news/HUMANIGEN-INC-MANAGEMENT-S-DISCUSSION-AND-ANALYSIS-OF-FINANCIAL-CONDITION-AND-RESULTS-OF-OPERATION-43386924/

Our current number of Outstanding Shares is 119.1M. Two times this number is 238.2M shares for our prospective business combination. These two numbers equals an OS of 357.3 M. The company would need even more shares for a Controlled Equity Offering.

We haven't seen a prospectus or other filing regarding an increase in our OS for an equity offering. So how are we going to proceed?

I think we'll forward split at 5:1. There is a revised OS already showing on the Ihub financial section for Humanigen which aligns perfectly with this thesis. It reflects Shares Outstanding of 595,400,675. Divide this number by 5 equals 119.08, our current OS. The shares then available for a Controlled Equity Offering would be the difference between 595.4M - 357.3M = 238.1M shares.

The forward split would drop our share price from $0.17 to $0.034. To meet all of the Nasdaq listing standards, we need a minimum bid price pf $1.00. So we need news. We have several catalysts, to include Long Covid, government stockpiling, CMML, GvHD, asthma/arthritis partnerships, regulatory approval or authorization based on the ACTIV-5 Final Report or interim analysis of the CMML data, etc.

We were previously selling for over $30 per share with much less short term potential. We lost a major opportunity by the FDA/NIAID/NIH delays getting us into the Covid market. On the other hand, the products that got the covid revenue we should have been earning are useless now. And Covid is still the third leading cause of death in the US, with a market that could be all ours, especially if lenz could be used prophylactically.

https://www.webmd.com/covid/news/20230417/covid-remains-leading-cause-of-death-us

I have no idea of how feasible this scenario is. It just makes sense to me.